Shots:Clinical-stage biopharma companies are in constant need of funding and the best way to pull in money in such dire situations is by going public. 2023 had been a great year for Wall Streets across the globe with continuous announcements of IPOsKenvue by bagging $4.37B upon completion of its IPO ranked first in…
Shots: New Year, New Us! Our hand-curated “Know Your Investor” reports will now be exploring leading investors of 2023 Founded in 2002, RA Capital forged ahead to become a key investor in life science and healthcare companies. In 2023, RA Capital closed 40 major investments in biopharma companies, devices, manufacturing, service offering firms, and diagnostics …
Shots:Brian talked about the $17 million in Series A funding led by Blue Ledge Capital including other venturesBrian also spoke about multiple products being developed in Qnovia’s pipeline. The funding will advance its NRT drug candidate through an IND submission in 2023The interview gives an understanding of how Qnovia is developing innovative…
In an interview with PharmaShots, Ray Lee, CEO at Teclison shared his views on the completion of a $5.9 million capital raise and advancement of its oncology drug portfolioShots:Ray spoke about Teclison’s recently completed funding of $5.9 million led by W.T.T. InvestmentHe focused on the development of the lead candidate in the…
In an interview with PharmaShots, Konstantin Mehl, President, CEO, and Founder at Kaia Health shared his views on the grant of $75M Series C funding to expand clinical capabilities & transform the treatment path for musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) care in the US and EU.Shots:The funding will extend the offering within EU and…
Paige is a global digital pathology founded in 2017 by Thomas Fuchs, Dr. Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The company involves computational pathology products that are targeted for patients and their care teams for effective, more informed treatment decisions. Paige has developed a platform to deliver novel technology to pathologists to…

